Approval is based on multicohort trial, UTX-TGR-205.
-
FDA approves umbralisib for previously treated marginal zone and follicular lymphoma -
NICE draft guidance approves maintenance niraparib for gynaecological cancers The draft guidance is now open for public consultation until January 28, 2021, with the final guidance due next month.
-
NHS patients will be among the first in the world to be offered access to the CAR-T therapy.
-
R/R MCL: first CAR T-cell therapy fulfils unmet need Excerpts from an interview with a Harvard lymphoma specialist.
-
ASH 2020 — R/R PTCL: duvelisib shows promise in phase 2 trial Investigators are hopeful of an approval.
-
New ESMO guidelines on newly diagnosed and relapsed follicular lymphoma The updated ESMO Clinical Practice Guidelines provide key recommendations on the management of follicular lymphoma
-
B-cell lymphoma: CAR T-cell therapy may not be for all patients Dr. Zelenetz on an analysis of CIBMTR registry data at the NCCN Hematologic Malignancies Annual Congress.
-
Tazemetostat shows activity in skin and blood cancer Tazemetostat received accelerated FDA approval based on these findings.
-
The European Medicines Agency has recommended granting a licence for treatment with autologous anti-CD19-transduced CD3+ cell therapy.
-
All you need to know about tafasitamab for DLBCL Tafasitamab-cxix was recently approved by the US FDA.
-
OSA is linked to increased risk for non-Hodgkin lymphoma Retrospective cohort study of more than 2 million in Korea uncovers association.
-
Insights about treating newly diagnosed MCL Session presented at ASH 2020.
-
Napabucasin can inhibit DLBCL in vitro Drug tested on DLBCL cell lines.
-
NICE approves polatuzumab vedotin for relapsed B-cell lymphoma Polatuzumab vedotin with rituximab and bendamustine for relapsed or refractory diffuse large B-cell lymphoma